■肾细胞癌(RCC)是最常见的肾癌。本研究旨在评估E-cadherin的潜在预测价值,与肿瘤转移相关的上皮间质转运(EMT)过程的标志物。
■我们搜索了PubMed,Embase,和Cochrane图书馆来确定前瞻性研究。危险比(HR),赔率比(OR),并总结了95%置信区间(CIs),以验证E-cadherin与生存和临床特征之间的关系.使用NOS表评估纳入研究的质量。然后,我们使用带有dplyr软件包的R语言分析了癌症基因组图谱计划(TCGA)数据库中的遗传数据和临床特征进行验证.
■包括21篇文章。分析显示,高E-cadherin表达与良好预后之间存在很强的联系(对于OS,HR=0.35,95%CI:0.19-0.62;对于PFS,HR=0.19,95%CI:0.03-0.53;对于DSS,HR=0.25,95%CI:0.08-0.76;对于RFS,HR=0.71,95%CI:0.44-1.16;对于DFS,HR=0.28,95%CI:0.13-0.61;对于T期,OR=0.21,95%CI:0.11-0.41;对于N阶段,OR=0.07,95CI:0.02-0.25;对于M阶段,OR=0.12,95%CI:0.02-0.60;对于临床分期,OR=0.29,95%CI:0.18-0.47;对于核级,OR=0.23,95%CI:0.13-0.41;对于肿瘤大小,OR=0.49,95%CI:0.26-0.92)。该结果得到了使用TCGARCC患者队列的生物信息学分析的支持(P<0.01)。
■根据当前数据,E-cadherin可预测RCC患者的预后。
UNASSIGNED: Renal cell carcinoma (RCC) is the most common cancer of the kidney. This study aims to evaluate the potential predictive value of E-cadherin, a marker of the epithelial mesenchymal transit (EMT) process that has been associated with tumor metastasis.
UNASSIGNED: We searched PubMed, Embase, and Cochrane Library to identify prospective studies. Hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were summarized to validate the relationship between E-cadherin and survival and clinical characteristics. The quality of the included studies was assessed using the NOS table. Then, we analyzed genetic data and clinical characteristics from The Cancer Genome Atlas Program (TCGA) database using R language with the dplyr package for validation.
UNASSIGNED: Including 21 articles. The analysis revealed a strong link between high E-cadherin expression and favorable prognosis (for OS, HR = 0.35, 95% CI: 0.19-0.62; for PFS, HR = 0.19, 95% CI: 0.03-0.53; for DSS, HR = 0.25, 95% CI: 0.08-0.76; for RFS, HR = 0.71, 95% CI: 0.44-1.16; for DFS, HR = 0.28, 95% CI: 0.13-0.61; for T stage, OR = 0.21, 95% CI: 0.11-0.41; for N stage, OR = 0.07, 95%CI: 0.02-0.25; for M stage, OR = 0.12, 95% CI: 0.02-0.60; for clinical stage, OR = 0.29, 95% CI: 0.18-0.47; for nuclear grade, OR = 0.23, 95% CI: 0.13-0.41; for tumor size, OR = 0.49, 95% CI: 0.26-0.92). The findings were supported by bioinformatic analysis which used TCGA RCC patient\'s cohort (P < 0.01).
UNASSIGNED: Based on the current data, E-cadherin may predict a better prognosis in RCC patients.